Skip to main content

Breadcrumb

  1. Home

No risk adjustment or risk stratification

Combination chemotherapy or chemo-immunotherapy (if HER2 positive), is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0 or stage IB - III hormone receptor negative breast cancer

  • Percentage of female patients, age >= 18 and < 70 at diagnosis, who have their first diagnosis of cancer (epithelial malignancy), at AJCC stage T1cN0M0 or Stage IB - IIIC, whose primary tumor is of the breast, and progesterone and estrogen receptor negative is recommended or administered multi-agent chemotherapy within 4 months (120 days) of diagnosis

    CBE ID
    0559

Communication with the physician or other clinician managing on-going care post fracture for men and women aged 50 years and older

  • Percentage of adults 50 years and older treated for a fracture with documentation of communication, between the physician treating the fracture and the physician or other clinician managing the patient’s on-going care, that a fracture occurred and that the patient was or should be considered for osteoporosis treatment or testing. This measure is reported by the physician who treats the fracture and who therefore is held accountable for the communication.

    CBE ID
    0045

Community Acquired Pneumonia Admission Rate (PQI 11)

  • Discharges with a principal diagnosis of community acquired bacterial pneumonia per 100,000 population, age 18 or older. Excludes sickle cell or hemoglobin-S admissions, other indications of immunocompromised state admissions, obstetric admissions, and transfers from other institutions.

    [NOTE: The software provides the rate per population. However, common practice reports the measure as per 100,000 population. The user must multiply the rate obtained from the software by 100,000 to report admissions per 100,000 population.]

    CBE ID
    0279

Comprehensive Diabetes Care

  • The percentage of patients 18–75 years of age with diabetes (type 1 and type 2) who had each of the following:
    - Hemoglobin A1c (HbA1c) testing (NQF#0057)
    - HbA1c poor control (>9.0%) (NQF#0059)
    - HbA1c control (<8.0%) (NQF#0575)
    - HbA1c control (<7.0%) for a selected population*
    - Eye exam (retinal) performed (NQF#0055)
    - LDL-C screening (NQF#0063)
    - LDL-C control (<100 mg/dL) (NQF#0064)
    - Medical attention for nephropathy (NQF#0062)
    - BP control (<140/90 mm Hg) (NQF#0061)
    - Smoking status and cessation advice or treatment

    CBE ID
    0731